Beyond Speed: Why Upstream-Downstream Alignment Determines Success In Complex Biologics Like ADC

By Stephanie Wickham, Ph.D., Snr. Director of Development

Developing complex biologics like antibody-drug conjugates (ADCs) and bispecific antibodies demands a fundamental shift away from treating process stages as isolated steps. Reaching early clinical milestones quickly is no longer enough if the underlying process creates downstream bottlenecks, scale-up delays, or product heterogeneity.

True efficiency requires designing speed and robustness into the manufacturing pathway simultaneously. Decisions made during upstream development—such as cell culture environment and bioreactor scale-up parameters—directly influence product quality, impurity profiles, and downstream purification yields long before reaching chromatography columns. Meanwhile, rigorous analytical development serves as the critical thread connecting these stages, providing early data to guide decisions, track critical quality attributes, and prevent costly late-stage process redesigns.

Integrating upstream, downstream, and analytical strategies from the start safeguards program timelines and ensures scalable commercial success. Read the full article to discover how an aligned development framework optimizes complex biomanufacturing.